Autophagy-tethering compounds (ATTECs) as an emerging and potentially transformative drug discovery approach

Area of Science:

• Biochemistry
• Molecular Biology
• Medicinal Chemistry

Background:

• Targeted protein degradation (TPD) utilizes cellular machinery for disease treatment.
• The ubiquitin-proteasome system (UPS) degrades short-lived proteins, while the lysosome-mediated system (LMS) handles larger substrates.
• Autophagy-tethering compounds (ATTECs) leverage the autophagy-lysosome system (ALS) for targeted degradation.

Purpose of the Study:

• To review the therapeutic applications of ATTECs in human diseases.
• To highlight recent advancements in ATTEC development.
• To explore future opportunities for ATTEC expansion via ALS.

Main Methods:

• Review of existing literature on ATTECs and ALS.
• Analysis of ATTEC mechanisms and therapeutic potential.
• Medicinal chemistry perspective on ATTEC development.

Main Results:

• ATTECs represent a promising TPD strategy harnessing the ALS.
• These heterobifunctional molecules target disease-causing proteins.
• Recent progress shows significant therapeutic potential.

Conclusions:

• ATTECs offer a novel therapeutic modality for diseases.
• Further development through medicinal chemistry can expand ATTEC applications.
• Harnessing ALS provides new avenues for targeted degradation technologies.